Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system
- PMID: 11149247
- DOI: 10.1080/01616412.2000.11740761
Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system
Abstract
Glial cell line-derived neurotrophic factor (GDNF) is a member of the transforming growth factor beta superfamily and acts as a neurotrophic factor for the nigrostriatal dopaminergic system. GDNF at a dose of 100 micrograms was injected stereotactically into the striatum of Sprague-Dawley rats that had been treated with intrastriatal 6-hydroxydopamine (6-OHDA) injection four weeks earlier. Immunocytochemical and behavioral analyses showed significant recovery of the nigrostriatal dopaminergic system after a single GDNF injection or continuous GDNF injection. Immunocytochemical and behavioral study showed that there was no significant difference between the results obtained from the two different injection methods. This result demonstrates the potential usefulness of GDNF for the treatment of Parkinson's disease.
Similar articles
-
The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.Neurosci Res. 2000 Apr;36(4):319-25. doi: 10.1016/s0168-0102(00)00097-3. Neurosci Res. 2000. PMID: 10771110
-
Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.Eur J Neurosci. 2000 Nov;12(11):3871-82. doi: 10.1046/j.1460-9568.2000.00274.x. Eur J Neurosci. 2000. PMID: 11069582
-
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.Eur J Neurosci. 1999 May;11(5):1554-66. doi: 10.1046/j.1460-9568.1999.00566.x. Eur J Neurosci. 1999. PMID: 10215908
-
Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.Clin Exp Pharmacol Physiol. 2001 Nov;28(11):896-900. doi: 10.1046/j.1440-1681.2001.03544.x. Clin Exp Pharmacol Physiol. 2001. PMID: 11703392 Review.
-
Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.Brain Res. 2000 Dec 15;886(1-2):82-98. doi: 10.1016/s0006-8993(00)02915-2. Brain Res. 2000. PMID: 11119690 Review.
Cited by
-
Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.Int J Mol Sci. 2017 Oct 20;18(10):2190. doi: 10.3390/ijms18102190. Int J Mol Sci. 2017. PMID: 29053638 Free PMC article. Review.
-
The orphan nuclear receptor Nurr1 agonist amodiaquine mediates neuroprotective effects in 6-OHDA Parkinson's disease animal model by enhancing the phosphorylation of P38 mitogen-activated kinase but not PI3K/AKT signaling pathway.Metab Brain Dis. 2021 Apr;36(4):609-625. doi: 10.1007/s11011-021-00670-2. Epub 2021 Jan 28. Metab Brain Dis. 2021. PMID: 33507465
-
Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.Drugs Aging. 2014 Apr;31(4):239-61. doi: 10.1007/s40266-014-0160-x. Drugs Aging. 2014. PMID: 24610720 Review.
-
Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity.J Neuroimmunol. 2010 Aug 25;225(1-2):43-51. doi: 10.1016/j.jneuroim.2010.04.010. Epub 2010 May 14. J Neuroimmunol. 2010. PMID: 20471698 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
